These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36333179)

  • 1. Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort.
    Fainberg HP; Oldham JM; Molyneau PL; Allen RJ; Kraven LM; Fahy WA; Porte J; Braybrooke R; Saini G; Karsdal MA; Leeming DJ; Sand JMB; Triguero I; Oballa E; Wells AU; Renzoni E; Wain LV; Noth I; Maher TM; Stewart ID; Jenkins RG
    Lancet Digit Health; 2022 Dec; 4(12):e862-e872. PubMed ID: 36333179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation.
    Fainberg HP; Moodley Y; Triguero I; Corte TJ; Sand JMB; Leeming DJ; Karsdal MA; Wells AU; Renzoni E; Mackintosh J; Tan DBA; Li R; Porte J; Braybrooke R; Saini G; Johnson SR; Wain LV; Molyneaux PL; Maher TM; Stewart ID; Jenkins RG
    Lancet Respir Med; 2024 Sep; 12(9):681-692. PubMed ID: 39025091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.
    Jenkins RG; Simpson JK; Saini G; Bentley JH; Russell AM; Braybrooke R; Molyneaux PL; McKeever TM; Wells AU; Flynn A; Hubbard RB; Leeming DJ; Marshall RP; Karsdal MA; Lukey PT; Maher TM
    Lancet Respir Med; 2015 Jun; 3(6):462-72. PubMed ID: 25770676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease.
    Khan F; Stewart I; Howard L; McKeever TM; Jones S; Hearson G; Braybrooke R; Edwards C; Jenkins G; Saini G
    BMJ Open Respir Res; 2019; 6(1):e000439. PubMed ID: 31258922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.
    Durheim MT; Collard HR; Roberts RS; Brown KK; Flaherty KR; King TE; Palmer SM; Raghu G; Snyder LD; Anstrom KJ; Martinez FJ;
    Lancet Respir Med; 2015 May; 3(5):388-96. PubMed ID: 25890798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cluster phenotypes in a non-idiopathic pulmonary fibrosis fibrotic interstitial lung diseases cohort in Singapore.
    Kam MLW; Tiew PY; Chai HZ; Low SY
    J Thorac Dis; 2022 Jul; 14(7):2481-2492. PubMed ID: 35928611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study.
    Herazo-Maya JD; Sun J; Molyneaux PL; Li Q; Villalba JA; Tzouvelekis A; Lynn H; Juan-Guardela BM; Risquez C; Osorio JC; Yan X; Michel G; Aurelien N; Lindell KO; Klesen MJ; Moffatt MF; Cookson WO; Zhang Y; Garcia JGN; Noth I; Prasse A; Bar-Joseph Z; Gibson KF; Zhao H; Herzog EL; Rosas IO; Maher TM; Kaminski N
    Lancet Respir Med; 2017 Nov; 5(11):857-868. PubMed ID: 28942086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation.
    Stuart BD; Lee JS; Kozlitina J; Noth I; Devine MS; Glazer CS; Torres F; Kaza V; Girod CE; Jones KD; Elicker BM; Ma SF; Vij R; Collard HR; Wolters PJ; Garcia CK
    Lancet Respir Med; 2014 Jul; 2(7):557-65. PubMed ID: 24948432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling.
    Man A; Davidyock T; Ferguson LT; Ieong M; Zhang Y; Simms RW
    Rheumatology (Oxford); 2015 Aug; 54(8):1464-71. PubMed ID: 25784774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
    Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
    Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.
    Neighbors M; Cabanski CR; Ramalingam TR; Sheng XR; Tew GW; Gu C; Jia G; Peng K; Ray JM; Ley B; Wolters PJ; Collard HR; Arron JR
    Lancet Respir Med; 2018 Aug; 6(8):615-626. PubMed ID: 30072107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifetime spirometry patterns of obstruction and restriction, and their risk factors and outcomes: a prospective cohort study.
    Dharmage SC; Bui DS; Walters EH; Lowe AJ; Thompson B; Bowatte G; Thomas P; Garcia-Aymerich J; Jarvis D; Hamilton GS; Johns DP; Frith P; Senaratna CV; Idrose NS; Wood-Baker RR; Hopper J; Gurrin L; Erbas B; Washko GR; Faner R; Agusti A; Abramson MJ; Lodge CJ; Perret JL
    Lancet Respir Med; 2023 Mar; 11(3):273-282. PubMed ID: 36244396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
    JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
    Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
    Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
    Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial 6-month change in forced vital capacity predicts subsequent decline and mortality in Japanese patients with newly diagnosed idiopathic pulmonary fibrosis.
    Toi Y; Takei R; Kimura T; Kataoka K; Matsuda T; Yokoyama T; Fukuoka J; Johkoh T; Kondoh Y
    Respir Investig; 2021 May; 59(3):335-341. PubMed ID: 33551330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study.
    Adams CJ; Shapera S; Ryerson CJ; Assayag D; Johannson KA; Fell CD; Morisset J; Manganas H; Kolb M; Hambly N; Cox G; Khalil N; Marcoux V; Wilcox PG; To T; Sadatsafavi M; Halayko AJ; Gershon A; Garlick K; Fisher JH
    Respir Med; 2022 Jan; 191():106722. PubMed ID: 34959146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.